Pharmacogenetics and Age-Related Macular Degeneration

Table 2

Pharmacogenetics of photodynamic therapy.

Treatment	Genes	Result
PDT	CFH	CFH CC associated with worse visual outcomes [55]
PDT	CFH and ARMS2	CFH TT associated with worse visual outcomes, especially in predominantly classic CNV; no association with ARMS2 [56]
PDT	CFH	No association with PDT responders versus nonresponders [57]
PDT	CFH	No association with visual acuity outcomes [58]
PDT	ARMS2 and HTRA1	No association with visual acuity outcomes or number of PDT sessions with either gene [59]
PDT	CFH and CRP	No effect with CFH; 2 of 9 CRP polymorphisms associated with more favorable response to treatment [60]
PDT	CFH, HTRA1, VEGF, and PEDF	HTRA1 GG associated with more favorable treatment outcomes; combination of 2 CFH genotypes associated with reduced time interval until disease recurrence; no association with other genes [61]
PDT	VEGF	2 polymorphisms associated with response to treatment [62]
PDT	Multiple	In classic CNV, prothrombin and MTFHR associated with PDT responders; factor XIII-A associated with PDT nonresponders; factor V, methionine synthase; methionine synthase reductase not associated with PDT response [63]
		In occult CNV, combination of factor V and prothrombin associated with PDT responders; factor XIII-A associated with PDT nonresponders; MTFHR, methionine synthase; methionine synthase reductase not associated with PDT response [64]

CNV: choroidal neovascularization, PDT: photodynamic therapy.